EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Management of post‐autologous transplant relapse in patients with T‐cell lymphomas

Olivier Veilleux, Francisco Socola, Sally Arai, Matthew J Frank, Laura Johnston, Robert Lowsky, Judith Shizuru, Everett Meyer, Lori Muffly, Andrew R Rezvani, Parveen Shiraz, Surbhi Sidana iD und 4 weitere

American Journal of Hematology · 2024

DOI: 10.1002/ajh.27345 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Hematology, 2024. Verfasst von Olivier Veilleux und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Hôpital Maisonneuve-Rosemont, Montreal, Quebec, Canada. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Lymphoma, T-Cell, Peripheral. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Autologous hematopoietic cell transplantation (AHCT) is often used as a consolidation for patients with peripheral T‐cell lymphomas (PTCLs) due to the poor prognosis associated with this heterogenous group of disorders. However, a significant number of patients will experience post‐AHCT disease relapse. Here, we report a retrospective study of consecutive 124 patients with PTCLs who underwent AHCT from 2008 to 2020. With a median follow‐up of 6.01 years following AHCT, 49 patients (40%) experienced disease relapse. As expected, more patients who were not in first complete remission experienced post‐AHCT relapse. Following relapse, majority of the patients (70%) receiving systemic therapies intended as bridging to curative allogeneic HCT. However, only 18 (53%) patients eventually underwent allogeneic HCT. The estimated 3‐year OS among patients proceeding to allogeneic HCT was 72% (95% CI 46%–87%). Our report details the pattern of post‐AHCT relapse and the management of relapsed disease using different therapeutic modalities.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationLymphoma, T-Cell, PeripheralHumansMiddle AgedMaleFemaleAdultRetrospective StudiesAgedRecurrenceTransplantation, AutologousNeoplasm Recurrence, LocalYoung Adult

Autor:innen und Institutionen

  • Department of Medicine, Hôpital Maisonneuve-Rosemont, Montreal, Quebec, Canada.
  • Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA.

ORCID-Profile: Surbhi Sidana, Wen-Kai Weng

Zitieren

APA

Veilleux, O., Socola, F., Arai, S., Frank, M. J., Johnston, L., Lowsky, R., Shizuru, J., Meyer, E., Muffly, L., Rezvani, A. R., Shiraz, P., Sidana, S., Dahiya, S., Miklos, D. B., Negrin, R. S., & Weng, W. K. (2024). Management of post‐autologous transplant relapse in patients with T‐cell lymphomas. American Journal of Hematology. https://doi.org/10.1002/ajh.27345

Vancouver

Veilleux O, Socola F, Arai S, Frank MJ, Johnston L, Lowsky R, et al. Management of post‐autologous transplant relapse in patients with T‐cell lymphomas. American Journal of Hematology. 2024. doi:10.1002/ajh.27345

BibTeX
@article{Veilleux2024,
  author = {Veilleux, Olivier and Socola, Francisco and Arai, Sally and Frank, Matthew J and Johnston, Laura and Lowsky, Robert and Shizuru, Judith and Meyer, Everett and Muffly, Lori and Rezvani, Andrew R and Shiraz, Parveen and Sidana, Surbhi and Dahiya, Saurabh and Miklos, David B and Negrin, Robert S and Weng, Wen-Kai},
  title = {Management of post‐autologous transplant relapse in patients with T‐cell lymphomas},
  journal = {American Journal of Hematology},
  year = {2024},
  doi = {10.1002/ajh.27345}
}
Kostenlos starten →